Conception, preparation and properties of functional carrier particles for pulmonary drug delivery

International Journal of Pharmaceutics

Volumn 433, Issue 1-2, 2012, Pages 51-59

  Odziomek, Marcin ^a   Sosnowski, Tomasz R ^a   Gradoń, Leon ^a  

^a WARSAW UNIVERSITY OF TECHNOLOGY   (Poland)

Author keywords

Functional carriers; Mucociliary clearance; Mucus; Powder properties; Spray drying

Indexed keywords

ACETYLCYSTEINE; DEXTRAN; DRUG CARRIER; MANNITOL;

AEROSOL; AQUEOUS SOLUTION; ARTICLE; CONTROLLED STUDY; DRUG DELIVERY SYSTEM; GLASS TRANSITION TEMPERATURE; MOISTURE; PARTICLE SIZE; POWDER; PRIORITY JOURNAL; SCANNING ELECTRON MICROSCOPY; SPRAY DRYING; THERMODYNAMICS;

ACETYLCYSTEINE; ADMINISTRATION, INHALATION; AEROSOLS; DEXTRANS; DRUG CARRIERS; DRUG DELIVERY SYSTEMS; DRUG STABILITY; DRUG STORAGE; DRY POWDER INHALERS; EXPECTORANTS; HUMIDITY; MANNITOL; MICROSCOPY, ELECTRON, SCANNING; PARTICLE SIZE; PHASE TRANSITION; POWDERS; TEMPERATURE; THERMODYNAMICS; TISSUE DISTRIBUTION;

EID: 84862890201     PISSN: 03785173     EISSN: 18733476     Source Type: Journal    
DOI: 10.1016/j.ijpharm.2012.04.067     Document Type: Article

References (77)

1. Adi, H., Young, P.M., Chan, H.K., Agus, H., Traini, D., 2010. Co-spray-dried mannitol-ciprofloxacin dry powder inhaler formulation for cystic fibrosis and chronic obstructive pulmonary disease. Eur. J. Pharm. Sci. 40, 239-247.
2. Anderson, S.D., Brannan, J., Spring, J., Spalding, N., Rodwell, L.T., Chan, H-K., Gonda, I., Walsh, A., Clark, A.R., 1997. A new method for bronchial provocation testing in asthmatic subjects using a dry powder of mannitol. Am. J. Respir. Crit. Care Med. 156, 758-765. (Pubitemid 27396412)
3. Arturson, G., Wallenius, G., 1964. The intravascular persistence of dextran of different molecular size in normal humans. Scand. J. Clin. Lab. Invest. 16, 76-80.
4. Bansil, R., Turner, B.S., 2006. Mucin structure aggregation, physiological functions and biomedical applications. Curr. Opin. Colloid Interface Sci. 11, 164-170. (Pubitemid 43867390)
5. Barghouthi, S., Guerdoud, L.M., Speert, D.P., 1996. Inhibition by dextran of Pseudomonos oeruginosa adherence to epithelial cells. Am. J. Respir. Crit. Care Med. 154, 1768-1793.
6. Barnes, P.J., 2004. Distribution of receptor targets in the lung. Proc. Am. Thor. Soc. 1, 345-351.
7. Barrowcliffe, M.P., Zanelli, G.D., Ellison, D., Jones, J.G., 1990. Clearance of charged and uncharged dextrans from normal and injured lung. J. Appl. Physiol. 68, 341-347. (Pubitemid 20075253)
8. Bhat, P.G., Flanagan, D.R., Donovan, M.D., 1996. Drug diffusion through cystic fibrotic mucus: steady-state permeation, rheologic properties, and glycoprotein morphology. J. Pharm. Sci. 85, 624-630. (Pubitemid 26179102)
9. Bosquillon, C., Lombry, C., Preat, V., Vanbever, R., 2001a. Comparison of particle sizing techniques in the case of inhalation dry powders. J. Pharm. Sci. 90, 2032-2041. (Pubitemid 33144449)
10. Bosquillon, C., Lombry, C., Preat, V., Vanbever, R., 2001b. Influence of formulation excipients and physical characteristics of inhalation dry powders on their aerosolization performance. J. Control. Release 70, 329-339. (Pubitemid 32155456)
11. Boucher, R.C., 1994. Human airway ion transport-part one. Am. J. Respir. Crit. Care Med. 150, 271-281.
12. Bradberry, C.C., 1991. Pharmaceutical composition comprising sodium cromoglycate and a mucolytic agent. EP 0 212 927 B1 Europe.
13. Brannan, J., Anderson, S.D., Perry, C.P., Freed-Martens, R., Lassig, A.R., Charlton, B., 2005. The safety and efficacy of inhaled dry powder mannitol as a bronchial provocation test for airway hyperresponsiveness: a phase 3 comparison study with hypertonic (4.5%) saline. Respir. Res. 6, 144.
14. Chow, A.H., Tong, H.H., Chattopadhyay, P., Shekunov, B.Y., 2007. Particle engineering for pulmonary drug delivery. Pharm. Res. 24, 411-437. (Pubitemid 46295160)
15. Codrons, V., Vanderbist, F., Verbeeck, R.K., Arras, M., Lison, D., Preat, V., Vanbever, R., 2003. Systemic delivery of parathyroid hormone (1-34) using inhalation dry powders in rats. J. Pharm. Sci. 92, 938-950. (Pubitemid 36523439)
16. Cone, R.A., 2009. Barrier properties of mucus. Adv. Drug Deliv. Rev. 61, 75-85.
17. Daniher, D.J., Zhu, J., 2008. Dry powder platform for pulmonary drug delivery. Particuology 6, 225-238.
18. Dolovich, M.B., 1997. Aerosols. In: Barnes, P.J., Grunstein, M.M., Leff, A.R., Woolcock, A.J. (Eds.), Asthma. Lippincott-Raven Publishers, Philadelphia, pp. 1349-1366.
19. Dubick, M.A., Wade, C.E., 1994. A review of the efficacy and safety of 7.5% NaCl/6% dextran 70 in experimental animals and humans. J. Trauma 36, 323-330. (Pubitemid 24109450)
20. Elversson, J., Millqvist-Fureby, A., 2005. Particle size and density in spray drying-effects of carbohydrate properties. J. Pharm. Sci. 94, 2049-2060. (Pubitemid 41551488)
21. Feng, W., Nakamura, S., Sudo, E., Lee, M.M., Shao, A., King, M., 1999. Effect of dextran on tracheal mucociliary velocity in dogs in vivo. Pulm. Pharmacol. Ther. 12, 35-41. (Pubitemid 29201618)
22. Feng, W., Garrett, H., Speert, D.P., King, M., 1998. Improved clearability of cystic fibrosis sputum with dextran treatment in vitro. Am. J. Respir. Crit. Care Med. 157, 710-714.
23. Feng, W., Speert, D.P., King, M., 1997. Effect of dextran molecular weight on CF sputum rigidity: further evidence for the mechanism of action. Pediatr. Pulmonol. 14S, 273.
24. Ferrari, S., Kitson, C., Farley, R., Steel, R., Marriot, C., Parkins, D.A., Scarpa, M., Wainwright, B., Evans, M.J., Coledge, W.H., Geddes, D.M., Alton, M., 2001. Mucus altering agents as adjuncts for nonviral gene transfer to airway epithelium. Gene Ther. 8, 1380-1386. (Pubitemid 32895668)
25. Frijlink, H.W., De Boer, A.H., 2004. Dry powder inhalers for pulmonary drug delivery. Expert Opin. Drug Deliv. 1, 67-86. (Pubitemid 40297957)
26. Gac, J., Gradoń, L., 2011. Modelling of spray drying of multicomponent systems. Inz. Ap. Chem. 50, 32-33 (in Polish).
27. Gilboa, A., Silberberg, A., 1976. In situ rheological characterization of epithelial mucus. Biorheology 13, 59-65.
28. Gniewek, P., Kolinski, A., 2010. Coarse-grained Monte Carlo simulations of mucus: structure dynamics and thermodynamics. Biophys. J. 99, 3507-3516.
29. Gradoń, L., 2009. Resuspension of particles from surfaces. Technological, environmental and pharmaceutical aspects. Adv. Powder Technol. 20, 17-28.
30. Granderton, D., Kassem, N.M., 1992. Dry powder inhalers. In: Dalby, R.N., Byron, P.R., Farr, S.T. (Eds.), Advanced Pharmaceutical Science. Academic Press, London, pp. 165-191.
31. Hancock, B.C., Zografi, G., 1993. The relationship between the glass transition temperature and the water content of amorphous pharmaceutical solids. Pharm. Res. 11, 471-477.
32. Hickey, A.J., 2004. Pharmaceutical Inhalation Aerosol Technology, 2nd edition. Marcel Dekker, New York.
33. Hirji, M., Franklin, R., Feng, W., Boyd, W.A., King, M., 1998. Effect of oligomeric chain length on mucolytic and mucokinetic effects of oligosacharides. Am. J. Respir. Crit. Care Med. 159, A685.
34. Hooton, J.C., Jones, M.D., Price, R., 2006. Predicting the behavior of novel sugar carriers for dry powder inhaler formulations via the use of a cohesive-adhesive force balance approach. J. Pharm. Sci. 95, 1288-1297. (Pubitemid 43874442)
35. Hulse, W.L., Forbes, R.T., Bonner, M.C., Getrost, M., 2009. The characterization and comparison of spray-dried mannitol samples. Drug Dev. Ind. Pharm. 35, 712-718.
36. Iiboshi, Y., 1996. Developmental changes in distribution of the mucous gel layer and intestinal permeability in rat small intestine. J. Parenter. Enteral. Nutr. 20, 406-411. (Pubitemid 26399216)
37. Iskandar, F., Nanodiyanto, A., Widijastuti, W., Young, L.S., Okuyama, K., Gradoń, L., 2009. Production of morphology-controllable porous hyaluronic acid particles using a spray-drying method. Acta Biomater. 5, 1027-1034.
38. Islam, I.U., Langrish, T.A., 2009. Comparing the crystallization of sucrose and lactose in spray dryers. Food Bioprod. Process. 87, 87-95.
39. Islam, N., Stewart, P., et al., 2005. Surface roughness contribution to the adhesion force distribution of salmeterol xinafoate on lactose carriers by atomic force microscopy. J. Pharm. Sci. 94, 1500-1511. (Pubitemid 41168680)
40. Jaques, A., Daviskas, E., Turton, J.A., McKay, K., Cooper, P., Stirling, R.G., Robertson, C.F., Bye, P.T.P., LeSouef, P.N., Shadbolt, B., Anderson, S.D., Charlton, B., 2008. Inhaled mannitol improves lung function in cystic fibrosis. Chest 133, 1388-1396. (Pubitemid 351892995)
41. Kaialy, W., Momin, M.N., Ticehurst, M.D., Murphy, J., Nokhodchi, A., 2010. Engineered mannitol as an alternative carrier to enhance deep lung penetration of salbutamol sulphate from dry powder inhaler. Colloids Surf. B: Biointerfaces 79, 345-356.
42. Karhu, M., Kuikka, J., Kauppinen, T., Bergstro, K., Vidgren, M., 2000. Pulmonary deposition of lactose carriers used in inhalation powders. Int. J. Pharm. 196, 95-103. (Pubitemid 30089518)
43. Khanvilkar, K., Donovan, M.D., Flanagan, D.R., 2001. Drug transfer through mucus. Adv. Drug Deliv. Rev. 48, 173-193. (Pubitemid 32434402)
44. Kim, C.S., Mungen, A.E., Eldridge, A., Wanner, A., 1988. Airway responsiveness to inhaled and intravenous carbachol in sheep: effect of airway mucus. J. Appl. Physiol. 65, 2744-2751. (Pubitemid 19026447)
45. King, M., 2005. Mucus and its role in airway clearance and cytoprotection. In: Qutayba, H., Shannon, J., Martin, J. (Eds.), Physiologic Basis of Respiratory Disease. BC Decker Inc., Hamilton, pp. 409-416.
46. King, M., Rubin, B.K., 2002. Pharmacological approaches to discovery and development of new mucolytic agents. Adv. Drug Deliv. Rev. 54, 1475-1490. (Pubitemid 35375771)
47. King, M., Kelly, S., Costo, M., 1985. Alternation of airway reactivity by mucus. Respir. Physiol. 62, 47-59.
48. Kumon, M., Kwok, P.C.L., Adi, H., Heng, D., Chan, H.K., 2010. Can low-dose combination products for inhalation be formulated in single crystalline particles? Eur J. Pharm. Sci. 40, 16-24.
49. Kramek-Romanowska, K., Odziomek, M., Sosnowski, T.R., Gradoń, L., 2011. Effects of process variables on the properties of spray-dried mannitol and mannitol/disodium cromoglycate powders suitable for drug delivery by inhalation. Ind. Eng. Chem. Res. 50, 13922-13931.
50. Lipworth, B.J., 1996. Pharmacokinetics of inhaled drugs. Br. J. Clin. Pharmacol. 42, 697-705. (Pubitemid 26417610)
51. Louey, M.D., Razia, S., Stewart, P.J., 2003. Influence of physico-chemical carrier properties on the in vitro aerosol deposition from interactive mixtures. Int. J. Pharm. 252, 87-98. (Pubitemid 36126617)
52. Matsuyama, T., Morita, T., Horikiri, Y., Yamahara, H., Yoshino, H., 2006. Enhancement of nasal absorption of large molecular weight compounds by combination of mucolytic agent and nonionic surfactant. J. Control. Release 110, 347-352. (Pubitemid 41827488)
53. Meyer, F.A., 1977. Comparison of structural glycoproteins from mucus of different sources. Biochim. Biophys. Acta 493, 272-282. (Pubitemid 8160592)
54. Newhouse, M.T., Hirst, P.H., Duddu, S.P., Walter, Y.H., Tarara, T.E., Clark, A.R., Weers, J.G., 2003. Inhalation of dry powder tobramycin PulmoSphere formulation in healthy volunteers. Chest 124, 360-363.
55. Patton, J.S., Brain, J.D., Davies, L.A., Fiegel, J., Gumbleton, M., Kwang, J.K., Sakagami, M., Vanbever, R., Ehrhardt, C., 2010. The particle has landed-characterizing the fate of inhaled pharmaceuticals. J. Aerosol Med. Pulm. Drug Deliv. 23, S71-S87.
56. Patton, J.S., Byron, P.R., 2007. Inhaling medicines: delivering drugs to the body through the lungs. Nat. Rev. Drug Discov. 6, 67-74. (Pubitemid 46020287)
57. Patton, J.S., 1996. Mechanisms of macromolecule absorption by the lungs. Adv. Drug Deliv. Rev. 19, 3-36. (Pubitemid 26167852)
58. Patton, J.S., Platz, R.M., 1992. Pulmonary delivery of peptides and proteins for systemic action. Adv. Drug Deliv. Rev. 8, 179-228.
59. Pilcer, G., Wauthoz, N., Amighi, K., 2012. Lactose characteristics and the generation of the aerosols. Adv. Drug Deliv. Rev. 64, 233-256.
60. Robinson, M., Daviskas, E., Eberl, S., Baker, J., Chan, H.K., Anderson, S.D., Bye, P.T., 1999. The effect of inhaled mannitol on bronchial mucus clearance in cystic fibrosis patients: a pilot study. Eur. Respir. J. 14, 678-685. (Pubitemid 29479736)
61. Sakagami, M., 2004. Insulin disposition in the lung following oral inhalation in humans: meta-analysis of its pharmacokinetics. Clin. Pharmacokinet. 43, 539-552. (Pubitemid 38858306)
62. Schneeberger, E.E., 1978. Structural basis for some permeability properties of the air-blood barrier. Fed. Proc. 37, 2471-2478. (Pubitemid 9033819)
63. Schneeberger, E.E., McCormack, J.M., 1984. Intercellular junctions in upper airway submucosal glands of the rat: a tracer and freeze-fracture study. Anat. Rec. 210, 421-433. (Pubitemid 15209464)
64. Smyth, H.D.C., Hickey, A.J., 2005. Carriers in drug powder delivery. Implications for inhalation system design. Am. J. Drug Deliv. 3, 117-132. (Pubitemid 41018283)
65. Sosnowski, T.R., Gradoń, L., 2010. Modification of inhalable powders by pulmonary surfactant components adsorbed on droplets during spray-drying process. Colloid Surf. A 365, 56-61.
66. Steckel, H., Markefka, P., et al., 2006. Effect of milling and sieving on functionality of dry powder inhalation products. Int. J. Pharm. 309, 51-59. (Pubitemid 43129464)
67. Steckel, H., Bolzen, N., 2004. Alternative sugars as potential carriers for dry powder inhalations. Int. J. Pharm. 270, 297-306. (Pubitemid 38077109)
68. Stern, M., Caplen, N.J., Browning, J.E., Griesenbach, U., Sorgi, F., Huang, L., Gruenert, D.C., Marriot, C., Crystal, R.G., Geddes, M.G., Alton, E.W., 1998. The effect of mucolytic agents on gene transfer across a CF sputum barrier in vitro. Gene Ther. 5, 91-98. (Pubitemid 28045074)
69. Takatsuka, S., Morita, T., Horikiri, Y., Yamahara, H., Saji, H., 2008. Influence of various combinations of mucolytic agent and non-ionic surfactant on intestinal absorption of poorly absorbed hydrophillic compounds. Int. J. Pharm. 349, 94-100. (Pubitemid 350299692)
70. Tang, P., Chan, H.K., Chiou, H., Ogawa, K., Jones, M.D., Adi, H., Buckton, G., Prud'homme, R.P., Raper, R.J., 2009. Characterisation and aerosolisation on mannitol particles produced via confined liquid impinging jets. Int. J. Pharm. 367, 51-57.
71. Tee, S.K., Marriott, C., Zeng, X.M., Martin, G.P., 2000. The use of different sugars as fine and coarse carriers for aerosolized salbutamol sulphate. Int. J. Pharm. 208, 111-123.
72. Torvela, T., Lahde, A., Monkare, J., Riikonen, J., Lehtinen, K.E.J., Jarvinen, K., Lehto, V.P., Jokiniemi, J., Joutsensaari, J., 2011. Low-temperature aerosol flow reactor method for preparation of surface stabilized pharmaceutical nanocarriers. J. Aerosol Sci. 42, 645-656.
73. Vehring, R., 2008. Pharmaceutical particle engineering via spray drying. Pharm. Res. 25, 999-1002.
74. Vodak, D.T., Dobry, D.E., Friesen, D., Reed, M., Gigliotti, A.P., Kuehl, P., Lyon, D.K., 2011. Dextran-based materials as excipients in engineered particle formulations: tailoring physical properties to optimize performance. Manufacturability and safety. In: Dalby, R.N., Byron, P.R., Peart, J., Suman, J.D., Young, P.M. (Eds.), RDD Europe 2011. Virgina Commonwealth University, Richmond, pp. 125-134.
75. Young, L.S., Gradoń, L., Janeczko, S., Iskandar, F., Okuyama, K., 2010. Formulation of highly ordered nanostructures by drying micrometer colloidal droplets. ACS Nano 4, 4714-4724.
76. Young, P.M., Chan, H.-K., et al., 2007a. The influence of mechanical processing of dry powder inhaler carriers on drug aerosolization performance. J. Pharm. Sci. 96, 1331-1341. (Pubitemid 46804584)
77. Zeng, X.M., Martin, G.P., et al., 1999. Effects of particle size and adding sequence of fine lactose on the deposition of salbutamol sulphate from a dry powder formulation. Int. J. Pharm. 182, 133-144. (Pubitemid 29248842)